Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma

Lijun CHEN; Yichen WANG; Qiang ZHENG; Yue WANG; Yan JIN; Yuan LI

doi:10.19401/j.cnki.1007-3639.2023.05.007

您当前的位置：

首页 >

文章列表页 >

Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma

Article | 更新时间：2025-12-31

- Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma
- China Oncology Vol. 33, Issue 5, Pages: 469-477(2023)
- 作者机构：
  
  复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.05.007
  CLC： R735.1
- Received：17 October 2022，
  
  Revised：2023-03-21，
  
  Published：30 May 2023
- 稿件说明：
移动端阅览
Lijun CHEN, Yichen WANG, Qiang ZHENG, et al. Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma[J]. China Oncology, 2023, 33(5): 469-477.
DOI：

Lijun CHEN, Yichen WANG, Qiang ZHENG, et al. Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma[J]. China Oncology, 2023, 33(5): 469-477. DOI： 10.19401/j.cnki.1007-3639.2023.05.007.

摘要

背景与目的：

程序性死亡[蛋白

]

配体-1（programmed death ligand-1，PD-L1）是食

管癌免疫治疗应用最广泛的疗效预测生物标志物，准确可靠的PD-L1检测对于筛查免疫治疗的潜在受益者至关重要。本研究旨在探讨食管鳞状细胞癌（esophageal squamous cell carcinoma，ESCC）患者PD-L1的表达情况以及7种不同克隆号PD-L1抗体免疫组织化学（immunohistochemistry，IHC）检测的一致性，为规范食管癌PD-L1 IHC检测及后续临床研究提供参考。

方法：

收集2020年1月—2021年12月复旦大学附属肿瘤医院的146例ESCC手术切除标本，用PD-L1 22C3、SP263、28-8、E1L3N XP、CST E1L3N、BP6099和MXR006 7种克隆号抗体进行染色，并采用联合阳性评分（comprehensive positive score，CPS）、肿瘤细胞比例评分（tumor proportion score，TPS）和免疫细胞评分（immune cell proportion score，IPS）3种评分标准，在不同临界值下对抗体的一致性进行统计学分析。

结果：

PD-L1 22C3与两种伴随诊断抗体（SP263、28-8）对比结果显示：CPS临界值为10时，3种抗体之间均一致性较好（Kappa：0.66 ~ 0.80）；CPS临界值为1时，28-8与22C3、SP263抗体一致性较好（Kappa=0.80、0.65），22C3与SP263一致性一般（Kappa=0.49）；TPS临界值为10%和1%时，3种抗体之间均具有很高的一致性（Kappa：0.79 ~ 0.89，0.71 ~ 0.91）。PD-L1 22C3与4种国产抗体（E1L3N XP、CST E1L3N、BP6099、MXR006）对比结果显示：CPS临界值为10和TPS临界值为10%时，5种抗体之间均一致性较好（Kappa：0.67 ~ 0.88，0.65 ~ 0.79）；CPS临界值为1时，5种抗体之间一致性较好或一般（Kappa：0.58 ~ 0.88）；TPS临界值为1%时，5种抗体之间均一致性很好（Kappa：0.85 ~ 0.92）；IPS临界值为1%和10%时，5种抗体之间一致性一般或较差（Kappa：0.46 ~ 0.66，0.30 ~ 0.62）。

结论：

PD-L1 22C3与两种伴随诊断抗体（SP263、28-8）在CPS和TPS中一致性较好；PD-L1 22C3与4种国产抗体（E1L3N XP、CST E1L3N、BP6099、MXR006）在CPS和TPS中一致性较好，而采用IPS时不同克隆号抗体的一致性较差。这些抗体之间具有一定的可互换性，可为食管鳞状细胞癌PD-L1临床检测提供更多选择。

Abstract

Background and purpose:

Immunohistochemistry (IHC) expression of programmed death ligand-1 (PD-L1) is the most widely used biomarker for predicting the efficacy of esophageal cancer immunotherapy

and accurate and reliable PD-L1 testing is crucial for screening potential beneficiaries of immunotherapy. This study aimed to investigate the expression of PD-L1 in patients with esophageal squamous cell carcinoma (ESCC) and the consistency and correlation of IHC detection of seven different clones of PD-L1 antibody

and to provide reference for the gradual standardization of PD-L1 IHC detection and follow-up clinical research of esophageal cancer.

Methods:

This study collected surgically resected and pathologically confirmed specimens from 146 ESC

C patients in Fudan University Shanghai Cancer Center from January 2020 to December 2021

and specimens were stained with seven antibodies: PD-L1 22C3

SP263

28-8

E1L3N XP

CST E1L3N

BP6099 and MXR006

respectively. The consistency of the antibodies was statistically analyzed in different cut-off values using three scoring criteria: comprehensive positive score (CPS)

tumor cell proportional score (TPS) and immune cell score (IPS).

Results:

The results of PD-L1 22C3

SP263 and 28-8 antibodies demonstrated that the consistency between the three antibodies was substantial (Kappa: 0.66-0.80) when CPS cut-off was 10

and the consistency of PD-L1 28-8 with 22C3 and SP263 antibodies was substantial (Kappa=0.80

0.65) whereas the consistency between PD-L1 22C3 and SP263 was moderate (Kappa=0.49) when CPS cut-off was 1. The three antibodies showed a high consistency when TPS cut-off was 10% and 1% (Kappa: 0.79-0.89

0.71-0.91). The companion diagnostic PD-L1 22C3 clone antibody and the four domestic clone antibodies E1L3N XP

CST E1L3N

BP6099 and MXR006 consistency study showed that the consistency between the five antibodies was substantial (Kappa: 0.67-0.88

0.65-0.79) when CPS cut-off was 10 and TPS cut-off was 10%

and the consistency between the five antibodies was substantial or moderate when CPS cut-off was 1 (Kappa: 0.58-0.88). When TPS cut-off was 1%

there was an excellent consistency between the five antibodies (Kappa: 0.85-0.92). Using IPS cut-off of 1% or 10%

the five antibodies showed moderate or poor consistency (Kappa: 0.30-0.62).

Conclusion:

PD-L1 22C3

SP263 and 28-8 antibodies showed high consistency. PD-L1 22C3 and four domestic antibodies PD-L1 E1L3N XP

CST E1L3N

BP6099 and MXR006 antibodies showed moderate consistency in CPS and TPS

while the consistency was poor in IPS. These antibodies are interchangeable with each other

providing more selectivity for clinical testing needs.

关键词

Keywords

references

李琦 , 李涛 , 范羽 , 等 . PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义 [J ] . 肿瘤预防与治疗 , 2018 , 31 ( 4 ) 248 - 257

LI Q , LI T , FAN Y , et al . Expression of PD-1/PD-L1 in esophageal squamous cell carcinoma and its clinical significance [J ] . J Cancer Control Treat , 2018 , 31 ( 4 ) 248 - 257

王程浩 , 韩泳涛 . 2020年中国临床肿瘤学会《食管癌诊疗指南》解读 [J ] . 肿瘤预防与治疗 , 2020 , 33 ( 4 ): 285 - 290 .

WANG C H , HAN Y T . Interpretation of the 2020 guidelines for the diagnosis and treatment of esophageal cancer by Chinese society of clinical oncology [J ] . J Cancer Control Treat , 2020 , 33 ( 4 ): 285 - 290 .

SHAH M A , KOJIMA T , HOCHHAUSER D , et al . Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study [J ] . JAMA Oncol , 2019 , 5 ( 4 ): 546 - 550 . DOI: 10.1001/jamaoncol.2018.5441 http://doi.org/10.1001/jamaoncol.2018.5441

KOJIMA T , SHAH M A , MURO K , et al . Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer [J ] . J Clin Oncol , 2020 , 38 ( 35 ): 4138 - 4148 . DOI: 10.1200/JCO.20.01888 http://doi.org/10.1200/JCO.20.01888 https://ascopubs.org/doi/10.1200/JCO.20.01888 https://ascopubs.org/doi/10.1200/JCO.20.01888

HUANG Z L , JIN Y , CAI X , et al . Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer [J ] . Thorac Cancer , 2022 , 13 ( 4 ): 523 - 532 . DOI: 10.1111/tca.v13.4 http://doi.org/10.1111/tca.v13.4 https://onlinelibrary.wiley.com/toc/17597714/13/4 https://onlinelibrary.wiley.com/toc/17597714/13/4

GUO W , WANG P , LI N , et al . Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis [J ] . Oncotarget , 2018 , 9 ( 17 ): 13920 - 13933 . DOI: 10.18632/oncotarget.23810 http://doi.org/10.18632/oncotarget.23810

BANG Y J , RUIZ E Y , VAN CUTSEM E , et al . Phase Ⅲ, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [J ] . Ann Oncol , 2018 , 29 ( 10 ): 2052 - 2060 . DOI: 10.1093/annonc/mdy264 http://doi.org/10.1093/annonc/mdy264 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341936 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341936

MURO K , CHUNG H C , SHANKARAN V , et al . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial [J ] . Lancet Oncol , 2016 , 17 ( 6 ): 717 - 726 . DOI: S1470-2045(16)00175-3 http://doi.org/S1470-2045(16)00175-3

JANJIGIAN Y Y , BENDELL J , CALVO E , et al . CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer [J ] . J Clin Oncol , 2018 , 36 ( 28 ): 2836 - 2844 . DOI: 10.1200/JCO.2017.76.6212 http://doi.org/10.1200/JCO.2017.76.6212

LEONE A G , PETRELLI F , GHIDINI A , et al . Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score [J ] . ESMO Open , 2022 , 7 ( 1 ): 100380 . DOI: 10.1016/j.esmoop.2021.100380 http://doi.org/10.1016/j.esmoop.2021.100380 https://linkinghub.elsevier.com/retrieve/pii/S2059702921003422 https://linkinghub.elsevier.com/retrieve/pii/S2059702921003422

HIRSCH F R , MCELHINNY A , STANFORTH D , et al . PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project [J ] . J Thorac Oncol , 2017 , 12 ( 2 ): 208 - 222 . DOI: S1556-0864(16)33536-5 http://doi.org/S1556-0864(16)33536-5

TSAO M S , KERR K M , KOCKX M , et al . PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project [J ] . J Thorac Oncol , 2018 , 13 ( 9 ): 1302 - 1311 . DOI: S1556-0864(18)30626-9 http://doi.org/S1556-0864(18)30626-9

KRIGSFELD G S , ZERBA K , NOVOTNY J Jr , et al . A comparative study of the PD-L1 IHC 22C3 and 28-8 assays on lung cancer samples [J ] . Int J Radiat Oncol , 2019 , 104 ( 1 ): 236 - 237 .

WATANABE T , OKUDA K , MURASE T , et al . Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma [J ] . Oncotarget , 2018 , 9 ( 29 ): 20769 - 20780 . DOI: 10.18632/oncotarget.25100 http://doi.org/10.18632/oncotarget.25100

DE RUITER E J , MULDER F J , KOOMEN B M , et al . Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) [J ] . Mod Pathol , 2021 , 34 ( 6 ): 1125 - 1132 . DOI: 10.1038/s41379-020-0644-7 http://doi.org/10.1038/s41379-020-0644-7 https://linkinghub.elsevier.com/retrieve/pii/S0893395222006020 https://linkinghub.elsevier.com/retrieve/pii/S0893395222006020

KRIGSFELD G S , PRINCE E , ZERBA K , et al . Analysis of real-world PD-L1 testing in patients with urothelial carcinoma [J ] . J Clin Oncol , 2019 , 37 ( 7_suppl ): 447 .

KARNIK T , KIMLER B F , FAN F , et al . PD-L1 in breast cancer: comparative analysis of 3 different antibodies [J ] . Hum Pathol , 2018 , 72 : 28 - 34 . DOI: S0046-8177(17)30281-2 http://doi.org/S0046-8177(17)30281-2

ADAM J , LE STANG N , ROUQUETTE I , et al . Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer [J ] . Ann Oncol , 2018 , 29 ( 4 ): 953 - 958 . DOI: S0923-7534(19)45464-1 http://doi.org/S0923-7534(19)45464-1

BÜTTNER R , GOSNEY J R , SKOV B G , et al . Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer [J ] . J Clin Oncol , 2017 , 35 ( 34 ): 3867 - 3876 . DOI: 10.1200/JCO.2017.74.7642 http://doi.org/10.1200/JCO.2017.74.7642

UDALL M , RIZZO M , KENNY J , et al . PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics [J ] . Diagn Pathol , 2018 , 13 ( 1 ): 12 . DOI: 10.1186/s13000-018-0689-9 http://doi.org/10.1186/s13000-018-0689-9

Views

2615

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

Expression of MMR in 515 cases of endometrioid adenocarcinoma and its correlation with clinicopathological features

SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing

Clinicopathological characteristics and prognostic analysis of medullary thyroid carcinoma in children and adolescents

Related Author

Ziyi LIAO

Yang PENG

Beilei ZENG

Yingying MA

Li ZENG

Kelun GAN

Daiyuan MA

Pathology Expert Group CD30-Positive Lymphoma

Related Institution

Department of Medical Oncology, Affiliated Hospital of Chuanbei Medical College, Nanchong

Department of Pathology, Shengjing Hospital of China Medical University

河北医科大学第四医院肿瘤免疫科

福建医科大学附属肿瘤医院，福建省肿瘤医院分子病理研究室

福建医科大学附属肿瘤医院，福建省肿瘤医院病理科

AI问答

⁰